Abstract:Background/Objectives: Critically ill patients admitted to the intensive care unit (ICU) frequently develop new-onset atrial fibrillation (NOAF) due to numerous risk factors. While NOAF has been associated with increased mortality, it remains unclear whether it serves merely as a marker of illness severity or directly contributes to adverse outcome. This study aimed to determine the incidence and risk factors for NOAF in a homogenized population of mechanically ventilated patients at ICU admission, excluding well-established predisposing factors. Additionally, we examined the impact of NOAF on mortality in this context. Methods: We prospectively studied consecutive patients over a 3-year period to identify triggers for NOAF. Factors associated with 30-day mortality during the ICU stay were recorded. Demographic data, medical history, laboratory findings, and the severity of illness at admission were compared between patients who developed NOAF and those remaining in sinus rhythm. In NOAF patients, the course of atrial fibrillation (resolution, persistence, or recurrence) was evaluated during the 30-day ICU stay. Results: Of the 1330 patients screened, 685 were eligible for analysis, with 110 (16.1%) developing NOAF. Septic episodes occurred more frequently in the NOAF group compared to the no-NOAF group (92.7% vs. 58.1%, p < 0.001). Notably, 80% of NOAF patients developed a septic episode concurrently with the atrial fibrillation, often stemming from secondary infections, and 85.3% presented with septic shock. When focusing on patients with at least one septic episode during the 30-day ICU stay, 23.4% of them developed NOAF. Additionally, patients with NOAF were older and had a higher prevalence of hypertension; disease severity at admission was not a triggering factor. Mainly sepsis, but also advanced age, and a history of hypertension remained independent factors associated with its occurrence. Sepsis, primarily, along with advanced age and a history of hypertension, was identified as independent factors associated with the occurrence of NOAF. Mortality was higher in the NOAF group compared to the control group (39 patients (35.5%) vs. 138 patients (24%), p = 0.01). NOAF occurrence, sepsis, disease severity at admission, and age were associated with increased ICU mortality; however, NOAF was not found to be an independent predictor of ICU mortality in multivariate analysis. Instead, sepsis, age, and disease severity at admission remained independent predictors of 30-day mortality. Sinus rhythm was restored in 60.9% of NOAF patients within 48 h, with the improvement or stabilization of sepsis being crucial for rhythm restoration. Conclusions: NOAF is a common complication in intubated ICU patients and is independently associated with sepsis, advanced age, and hypertension. While NOAF is linked to increased ICU mortality, it is more likely a marker of disease severity than a direct cause of death. Sepsis improvement appears critical for restoring and maintaining sinus rhythm.

Acute amiodarone‐induced pulmonary toxicity in adult ICU patients with new‐onset atrial fibrillation—A systematic review

Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review

New-onset Atrial Fibrillation in the Intensive Care Unit: Protocol for an International Inception Cohort Study (AFIB-ICU)

The management of new-onset atrial fibrillation in critical illness: an update on current therapeutic options

Atrial Fibrillation (AFIB) in the ICU: Incidence, Risk Factors, and Outcomes: The International AFIB-ICU Cohort Study

Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study

Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill

Evaluation of Amiodarone Administration in Patients with New-Onset Atrial Fibrillation in Septic Shock

Acute liver failure with amiodarone infusion: A case report and systematic review

Prevalence, Risk Factors, and Mortality of New-Onset Atrial Fibrillation in Mechanically Ventilated Critically Ill Patients

Complications of new-onset atrial fibrillation in critically ill COVID-19 patients admitted to the intensive care unit (ICU): a meta-analysis

Prognosis and Management of New‐onset Atrial Fibrillation in Critically Ill Patients

Interventions for the treatment of atrial fibrillation: a systematic literature review and meta-analysis

Impact of new-onset versus pre-existing atrial fibrillation on outcomes after transcatheter aortic valve replacement/implantation

Risk factors of new-onset postoperative atrial fibrillation in critically ill patients after non-cardiac surgery

Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias

Adverse effects of amiodarone therapy in adults with congenital heart disease

The effect of antiarrhythmic medications on the risk of cardiovascular outcomes in patients with atrial fibrillation and coronary artery disease

A systematic review and meta‐analysis of new‐onset atrial fibrillation in the context of COVID‐19 infection

Impact of Atrial Fibrillation and/or Flutter on in-Hospital Management and Outcomes in Non-ST Elevation Acute Coronary Syndromes

Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs